The FDA has approved an at-home starting dose for Leqembi IQLIK, the subcutaneous form of the Alzheimer's drug lecanemab, so patients beginning treatment no longer need an IV infusion to get started. The new regimen lets people with early Alzheimer's disease begin and continue treatment entirely by injection, administered at home, announced by Eisai and Biogen on July 13, 2026. This approval closes the one gap left after the subcutaneous maintenance dose reached the market in 2025: starting the drug still required IV infusions before switching to the weekly injection. Now both phases of treatment can run on the same at-home schedule, which changes what patients and caregivers need to plan for.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- Read the official guidance from Pharmatimes — Use this primary source to verify the official guidance.
- Read the official guidance from Alz — Use this primary source to verify the official guidance.
Table of Contents
- What Is the New Starting Dose, and How Is It Given?
- Comparing the At-Home Route to IV Infusion
- What the Approval Is Based On, and What It Means for Safety
- Cost and When the At-Home Starting Dose Becomes Available
- Frequently Asked Questions
What Is the New Starting Dose, and How Is It Given?
The approved starting regimen is 500 mg once weekly, delivered as two separate 250 mg injections from a prefilled autoinjector, according to Eisai and Biogen. Each injection takes about 15 seconds to administer, and a patient or caregiver gives both at the same sitting. This mirrors how the maintenance dose already works.
After the initiation phase, patients move to maintenance dosing of 360 mg once weekly, given as a single injection that also takes about 15 seconds, a dose the FDA approved in 2025, per the Alzheimer's Association. The practical difference is simply dose size: initiation uses two injections to deliver more drug at once, while maintenance uses one. The FDA granted this starting-dose application Priority Review, with a target decision date of May 24, 2026. The actual approval came after that date, per Eisai and Biogen.
Comparing the At-Home Route to IV Infusion
Patients and physicians can choose either intravenous or subcutaneous administration throughout treatment, and they may switch between the two as circumstances change, according to Eisai and Biogen. Neither route locks a patient in for the duration of treatment. The biggest practical difference is where treatment happens. Standard IV lecanemab requires a clinic visit every two weeks for the infusion itself, while the weekly subcutaneous dose can be self-administered by the patient or given by a caregiver at home, per the Alzheimer's Association.
That trades a less frequent clinic trip for a more frequent but far shorter at-home injection. For someone with mobility limits, transportation barriers, or a caregiver juggling a job, the at-home weekly injection removes a recurring half-day commitment to a clinic. For someone who prefers fewer total doses or wants a nurse present for each administration, the IV schedule still offers that structure. Either way, the choice doesn't have to be permanent.
What the Approval Is Based On, and What It Means for Safety
The FDA based this approval on results from subcutaneous sub-studies within Eisai's Phase 3 Clarity AD open-label extension trial in early Alzheimer's disease patients, according to Eisai. Eisai reported that rates of ARIA, or amyloid-related imaging abnormalities, were similar between patients on subcutaneous maintenance dosing and those on IV maintenance dosing, per the same Eisai data.
ARIA refers to swelling or small areas of bleeding in the brain that can show up on imaging during lecanemab treatment, sometimes without symptoms and sometimes with headache, confusion, or vision changes. Leqembi IQLIK's prescribing information carries a boxed warning for ARIA, the same serious warning that applies to the IV form, per Eisai and Biogen. Switching to the at-home injection route doesn't change this risk or the need for monitoring that comes with it.
Cost and When the At-Home Starting Dose Becomes Available
The subcutaneous maintenance autoinjector launched in the US on October 6, 2025, at a list price of $19,500 per year, according to American Pharmaceutical Review. The new at-home starting-dose option is planned to launch in the US in late August 2026, per the same report.
For a patient beginning treatment after that launch date, this means the entire course of lecanemab — both the initiation phase and ongoing maintenance — can potentially run through weekly at-home injections, without ever requiring an IV infusion visit. Patients already partway through IV initiation can discuss with their physician whether switching to the subcutaneous route makes sense for the remainder of their treatment.
Frequently Asked Questions
Can a patient switch from IV to subcutaneous Leqembi partway through treatment?
Yes. Patients and physicians can choose either route throughout treatment and switch between IV and subcutaneous administration as needed, according to Eisai and Biogen.
Does the at-home starting dose carry the same safety warnings as IV Leqembi?
Yes. Leqembi IQLIK carries the same boxed warning for ARIA, the brain swelling and microhemorrhage risk associated with IV lecanemab, per Eisai and Biogen.
How is the at-home starting dose different from the maintenance dose?
The starting dose is 500 mg weekly, given as two 250 mg injections, while maintenance is a single 360 mg weekly injection, both administered by autoinjector in about 15 seconds each, according to Eisai and Biogen and the Alzheimer's Association.
You Might Also Like
- PrecivityAD2 as an Adjunct to a 2026 Alzheimer’s Assessment: What Is Established and What Remains Uncertain for People With Mild Cognitive Impairment
- FDA’s 2026 Tauklarify Tau PET Imaging Approval: What Is Established and What Remains Uncertain for People With Mild Cognitive Impairment
- FDA’s 2026 PrecivityAD2 Alzheimer’s Blood Test Clearance: What Is Established and What Remains Uncertain for People With Mild Cognitive Impairment
